참고문헌
- Amling CL, Bergstralh EJ, Blute ML, et al (2001). Defining PSA progression after radical prostatectomy. What is the most appropriate cutoff? J Urol, 165, 1146 https://doi.org/10.1016/S0022-5347(05)66452-X
- Aus G, Abbou CC, Bolla M, et al (2006). Guidelines on Prostate Cancer. Ed EUA; Arnhem, EAU Guidelines Office. Chapter, 1, 106
- Bain BJ (2003). Bone marrow biopsy morbidity and mortality. Br J Haematol, 121, 949-51 https://doi.org/10.1046/j.1365-2141.2003.04329.x
- Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy, 1, 377-88. https://doi.org/10.1080/0032472031000141283
- Dotan ZA, Bianco FJ Jr, Rabini F, et al (2005). Pattern of PSA failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol, 23, 1962-8 https://doi.org/10.1200/JCO.2005.06.058
- Freedland SJ, Sutter ME, Dorey F, et al (2003). Defining the ideal cutoff point for determining PSA recurrence after radical prostatectomy. Urol, 61, 365-369 https://doi.org/10.1016/S0090-4295(02)02268-9
- Freedland SJ, Humphries EB, Mangold LA, et al (2007). Death in patients with recurrent prostate cancer after radical prostatectomy. PSA doubling time subgroups and their associated contributions to all cause mortality. J Clin Oncol, 25, 1765-71 https://doi.org/10.1200/JCO.2006.08.0572
- Hamilton RJ, Aronson WJ, Terris MK, et al (2008). Limitations of PSA doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol, 179, 1785-9. https://doi.org/10.1016/j.juro.2008.01.040
- Han M, Partin AW, Zahurak MW, et al (2003). Biochemical (PSA) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 169, 517-23 https://doi.org/10.1016/S0022-5347(05)63946-8
- Murray NP, Reyes E, Tapia P, et al (2012). Redefining micrometastasis in prostate cance-a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: implications in determining local or systemic treatment for biochemcial failure after radical prostatectomy. Int J Mol Med, 30, 896-904 https://doi.org/10.3892/ijmm.2012.1071
- NCCN (2014) prostate cancer guidelines. www.nccn.org NICE UK prostate cancer guidelines 2015. www.nccn.org
- Okotie OT, Aronson WJ, Wieder JA, et al (2004). Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol, 171, 2260-4 https://doi.org/10.1097/01.ju.0000127734.01845.99
- Partin AW, Pearson JD, Landis PK, et al (1994). Evaluation of serum PSA velocity after radical prostatectomy to distinguish local recurrence from systemic metastasis. Urol, 43, 649-59 https://doi.org/10.1016/0090-4295(94)90180-5
- Pound CR, Partin AW, Epstein JI, et al (1997). PSA after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Amm, 24, 395-406 https://doi.org/10.1016/S0094-0143(05)70386-4
- Scattoni V, Montorsi F, Picchio L, et al (2004). Diagnosis of locasl recurrence after radical prostatectomy. BJU Int, 93, 680-8 https://doi.org/10.1111/j.1464-410X.2003.04692.x
- Wood DP, Banerjee M (1997). Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease free survival. J Clin Oncol, 15, 3451-7. https://doi.org/10.1200/JCO.1997.15.12.3451
피인용 문헌
- The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy vol.07, pp.08, 2016, https://doi.org/10.4236/jct.2016.78062
- Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management vol.51, pp.1, 2018, https://doi.org/10.1186/s40659-018-0180-9